TICKERNERD
Menu
OABIOABIHealthcare · Biotechnology

OABI Stock Forecast: OmniAb, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.33
+0.70% on the day

The 7 Wall Street analysts covering OmniAb, Inc. hold a median 12-month price target of $8 — +84.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$629.5M
Ticker Nerd rank
93 / 100
Median analyst target
$8.00
Analysts covering
7
Total return, dividends reinvested
1W
+28.1%
1M
+107.2%
YTD
+134.1%
1Y
+140.6%
From 52W high
0.0%
From 52W low
+218.4%
$1.36
$4.33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OABI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OmniAb, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Revisions
89
Accruals
81
Value
68
Momentum
66
Quality
61
Issuance
52
Size
51
Volatility
38

Growth (96): Sales and profits are climbing, and climbing faster than before.

Volatility (38): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OABI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OABI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26OABIHigh $11.00Median $8.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $4.00Median $8.00High $11.00

The green dot is the last close — the median target sits +84.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$11
7 Aug 2025RBC CapitalMaintainsOutperform—
7 Aug 2025RBC CapitalMaintainsOutperform$4.00 → $3.00
12 May 2025BenchmarkReiteratesBuy—
27 Mar 2025RBC CapitalMaintainsOutperform—
20 Mar 2025BenchmarkMaintainsBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024BenchmarkReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
19 Aug 2024BenchmarkReiteratesBuy—
16 Aug 2024RBC CapitalReiteratesOutperform—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024BenchmarkReiteratesBuy—
26 Mar 2024Truist SecuritiesMaintainsBuy—
22 Mar 2024BenchmarkReiteratesBuy—
21 Mar 2024HC Wainwright & Co.ReiteratesBuy—
21 Mar 2024RBC CapitalReiteratesOutperform—
14 Nov 2023BenchmarkReiteratesBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023BenchmarkReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OABI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

OABI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

OmniAb, Inc. (OABI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.6×

Cheaper than 92% of US stocks

Price / sales
16.4×

Cheaper than 10% of US stocks

Price / book
2.4×

Cheaper than 41% of US stocks

EV / EBITDA
−27.6×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
244.2%

Higher than 97% of US stocks

Earnings growth (YoY)
244.2%

Higher than 92% of US stocks

Gross margin
95.5%

Higher than 98% of US stocks

Operating margin
−49.5%

Higher than 17% of US stocks

Net margin
−115.1%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−17.0%

Higher than 32% of US stocks

Return on assets
−8.3%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OABI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OABIOmniAb, Inc.$629.5M
93
SGMTSagimet Biosciences, Inc.$627.1M
31
EIKNEikon Therapeutics, Inc.$616.2M
2
PRMEPrime Medicine, Inc.$614.9M
33
CBIOCrescent Biopharma, Inc.$633.9M
56
VSTMVerastem, Inc.$605.2M
58
CRMDCorMedix, Inc.$642.4M
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OmniAb, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OABI news & analysis

OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech

Seeking Alpha · 18 Aug 2026positive

OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships such as its recent Eli Lilly collaboration. The Lilly deal validates OmniAb's technology, offers high-margin, capital-light economics, and has raised its 2026 cash guidance to $49–$53 million.

Why it matters — A OABI watcher would care because the Lilly partnership signals third-party validation of OmniAb's platform and strengthens its predictable milestone-revenue outlook and cash position.

OmniAb Raises 2026 Financial Guidance

Business Wire · 17 Aug 2026positive

OmniAb, Inc. (NASDAQ: OABI) raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. CEO Matt Foehr stated that recent business development and licensing activity enabled the company to again raise its 2026 financial guidance and significantly increase its cash outlook.

Why it matters — OmniAb watchers would care because the raised 2026 guidance signals improved cash outlook from recent technology licensing activity.

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

Business Wire · 17 Aug 2026positive

OmniAb announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program, leveraging OmniAb's technology platform and expertise in ion channel discovery and screening.

Why it matters — A collaboration with a major pharmaceutical company like Lilly could expand OmniAb's pipeline and validate its ion channel discovery platform.

OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

OmniAb, Inc. held its Q2 2026 earnings conference call, the transcript of which was published by Seeking Alpha. The call covered the company's financial results and operational developments for the quarter.

Why it matters — Earnings call transcripts provide investors and analysts with detailed insight into the company's quarterly financial performance, strategic direction, and management commentary.

OmniAb Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

OmniAb reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased. The company also raised its full-year 2026 revenue and year-end cash outlook.

Why it matters — A OABI watcher would care because improved quarterly results and an upward revision to the full-year 2026 revenue and cash outlook signal strengthening financial performance.

FAQ

Frequently asked questions about OABI stock

What is the OABI stock price forecast for 2026-2027?

The 7 Wall Street analysts covering OmniAb, Inc. have a median 12-month price target of $8, with estimates ranging from $4 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OABI stock a buy right now?

Of the 7 analysts covering OmniAb, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OmniAb, Inc. 93 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OABI?

As at 22 Aug 2026, OmniAb, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will OABI stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +84.8% from the last close, and Ticker Nerd's factor model ranks OmniAb, Inc. 93 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OABI stock forecast for 2030?

No analyst covering OmniAb, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OABI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $11 over the next 12 months.

How has OABI stock performed over the past year?

OmniAb, Inc. returned +140.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OmniAb, Inc. do?

OmniAb, Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies.

What is the latest news on OABI?

The most recent item we track (Seeking Alpha, 18 Aug 2026): "OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech". OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships such as its recent Eli Lilly collaboration. The Lilly deal validates OmniAb's technology, offers high-margin, capital-light economics, and has raised its 2026 cash guidance to $49–$53 million.

Company

About OmniAb, Inc.

OmniAb, Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. The company uses its proprietary technology platform, which leverages genetically engineered animals to generate a diverse range of antibodies. These antibodies are crucial for the development of drugs that can target a variety of diseases, ranging from cancer to autoimmune disorders. OmniAb collaborates with numerous pharmaceutical and biotech companies to create solutions that foster innovative treatments. One of the core features of OmniAb is its ability to streamline and enhance the drug discovery process, providing partners with access to high-quality antibodies. The company operates in a sector that is critical to advancing medical science and addressing some of the world's most challenging health conditions. By focusing on robust, versatile antibody generation, OmniAb plays a significant role in the pharmaceutical supply chain, ensuring that new therapies are both effective and efficient. In the financial market, OmniAb represents a part of the growing biotechnology industry, which is pivotal in driving advancements in medicine and increasing the longevity and quality of life. It stands as a notable innovator in the realm of antibody therapeutics.

CEO Mr. Matthew W. Foehr · 89 employees · United States · https://www.omniab.com